Topchoice Medical Co., Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Topchoice Medical Co., Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Shareholders might have noticed that Topchoice Medical Co., Inc. (SHSE:600763) filed its second-quarter result this time last week. The early response was not positive, with shares down 3.8% to CN¥41.19 in the past week. It looks to have been a decent result overall - while revenue fell marginally short of analyst estimates at CN¥702m, statutory earnings beat expectations by a notable 39%, coming in at CN¥0.43 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
股東們可能已經注意到,Topchoice Medical Co., Inc.(SHSE: 600763)上週這個時候公佈了第二季度業績。早期的反應並不樂觀,過去一週股價下跌3.8%,至41.19元人民幣。總體而言,這似乎是一個不錯的業績——雖然收入略低於分析師預期的70200萬元人民幣,但法定收益明顯超出預期的39%,爲每股0.43元人民幣。對於投資者來說,盈利是一個重要時刻,因爲他們可以追蹤公司的業績,查看分析師對明年的預測,看看對公司的情緒是否發生了變化。根據這些結果,我們收集了最新的法定預測,以了解分析師是否改變了盈利模式。
![1724799200906](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240828/42967760-0-d054f9c73d09ab715833c0c05703b872.webp/bigjpg)
Following the latest results, Topchoice Medical's eleven analysts are now forecasting revenues of CN¥3.04b in 2024. This would be a reasonable 5.2% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to increase 7.8% to CN¥1.22. Before this earnings report, the analysts had been forecasting revenues of CN¥3.18b and earnings per share (EPS) of CN¥1.28 in 2024. The analysts are less bullish than they were before these results, given the reduced revenue forecasts and the minor downgrade to earnings per share expectations.
根據最新業績,Topchoice Medical的11位分析師現在預測2024年的收入爲30.4元人民幣。與過去12個月相比,這將使收入合理增長5.2%。預計每股法定收益將增長7.8%,至1.22元人民幣。在本業績發佈之前,分析師一直預測2024年的收入爲31.8元人民幣,每股收益(EPS)爲1.28元人民幣。鑑於收入預期下降以及每股收益預期略有下調,分析師不如公佈業績之前那麼樂觀。
The analysts made no major changes to their price target of CN¥46.48, suggesting the downgrades are not expected to have a long-term impact on Topchoice Medical's valuation. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Topchoice Medical, with the most bullish analyst valuing it at CN¥55.69 and the most bearish at CN¥32.10 per share. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.
分析師沒有對46.48元人民幣的目標股價做出重大調整,這表明下調評級預計不會對Topchoice Medical的估值產生長期影響。但是,這並不是我們可以從這些數據中得出的唯一結論,因爲一些投資者在評估分析師目標股價時也喜歡考慮估計值的差異。對Topchoice Medical的看法有所不同,最看漲的分析師將其估值爲55.69元人民幣,最看跌的爲每股32.10元人民幣。這些目標股價表明,分析師對該業務的看法確實有所不同,但這些估計的差異不足以向我們表明,有些人押注取得巨大成功或徹底失敗。
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Topchoice Medical's past performance and to peers in the same industry. The period to the end of 2024 brings more of the same, according to the analysts, with revenue forecast to display 11% growth on an annualised basis. That is in line with its 10% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 13% annually. So although Topchoice Medical is expected to maintain its revenue growth rate, it's only growing at about the rate of the wider industry.
這些估計很有趣,但是在查看預測與Topchoice Medical過去的表現以及與同一行業的同行進行比較時,可以更粗略地描述一些細節。分析師表示,截至2024年底將帶來更多相同的情況,收入按年計算預計將增長11%。這與其在過去五年中10%的年增長率一致。相比之下,分析師估計(總計),整個行業的收入將每年增長13%。因此,儘管預計Topchoice Medical將保持其收入增長率,但其增長速度僅與整個行業差不多。
The Bottom Line
底線
The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Sadly, they also downgraded their revenue forecasts, but the business is still expected to grow at roughly the same rate as the industry itself. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
要了解的最重要的一點是,分析師下調了每股收益的預期,這表明公佈這些業績後,市場情緒明顯下降。遺憾的是,他們還下調了收入預期,但預計該業務的增長速度仍將與該行業本身大致相同。共識目標股價沒有實際變化,這表明該業務的內在價值與最新估計相比沒有發生任何重大變化。
With that in mind, we wouldn't be too quick to come to a conclusion on Topchoice Medical. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Topchoice Medical going out to 2026, and you can see them free on our platform here..
考慮到這一點,我們不會很快就Topchoice Medical得出結論。長期盈利能力比明年的利潤重要得多。在Simply Wall St,我們有分析師對Topchoice Medical到2026年的全方位估計,你可以在我們的平台上免費查看。
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Topchoice Medical that you should be aware of.
別忘了可能仍然存在風險。例如,我們已經確定了Topchoice Medical的1個警告信號,你應該注意這一點。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。